Hematological oncology includes the diagnosis and treatment of blood cancers and the diseases associated with blood. Our Hematologic Oncology Program offers patients with hematologic malignancies a range of medical therapies. One alternative is a stem cell transplant, medically known as a hematopoietic progenitor cell transplant, for some patients with blood cancer. Advances in stem cell research have streamlined conventional methods aimed at reducing risks and maximizing patient benefits. A transplant of the stem cells infuses healthy stem cells into the body. Stem cells from the bone marrow are stored, circulating (peripheral) from the bone marrow, circulating (peripheral) blood, and blood from the umbilical cord.
This procedure collects the patient's own stem cells, or harvests them, and freezes them before returning them to the patient following intensive chemotherapy and/or radiation treatment.
Transplant of stem cells in allogeneic form. Unlike an autologous stem cell transplant, an allogeneic stem cell transplant uses stem cells from a similar donor, such as a parent, an unknown person or a preserved blood from the umbilical cord.
You'll typically undergo a rehabilitation regimen before a stem cell transplant, which requires intensive treatment to kill as many cancer cells as possible. Such conditioning regimen will require high doses of chemotherapy, and radiation therapy (total body irradiation) in some cases. Many patients may get treatment with reduced dosage, which uses smaller, less toxic chemotherapy doses.
The patient will be able to undergo the transplant until complete. The stem cells are provided intravenously, much like a blood transfusion. Doctors will track the blood counts within months after the transplant. Red blood cell and platelet transfusions may be required.